These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34550840)

  • 1. Recent advances in lipopolysaccharide-based glycoconjugate vaccines.
    Zhu H; Rollier CS; Pollard AJ
    Expert Rev Vaccines; 2021 Dec; 20(12):1515-1538. PubMed ID: 34550840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx-/Wzy-dependent pathway enhances production of defined modal length O-polysaccharide polymers for use as haptens in glycoconjugate vaccines.
    Hegerle N; Bose J; Ramachandran G; Galen JE; Levine MM; Simon R; Tennant SM
    J Appl Microbiol; 2018 Aug; 125(2):575-585. PubMed ID: 29603538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production.
    Dow JM; Mauri M; Scott TA; Wren BW
    Expert Rev Vaccines; 2020 Jun; 19(6):507-527. PubMed ID: 32627609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines.
    Adamo R
    Acc Chem Res; 2017 May; 50(5):1270-1279. PubMed ID: 28463499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and Control of Sugar Size in Glycoconjugate Vaccines.
    Stefanetti G; MacLennan CA; Micoli F
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strain Selection for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive Nontyphoidal Salmonella Disease.
    Lanzilao L; Stefanetti G; Saul A; MacLennan CA; Micoli F; Rondini S
    PLoS One; 2015; 10(10):e0139847. PubMed ID: 26445460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.
    Micoli F; Adamo R; Costantino P
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29914046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoconjugate vaccines: current approaches towards faster vaccine design.
    Micoli F; Del Bino L; Alfini R; Carboni F; Romano MR; Adamo R
    Expert Rev Vaccines; 2019 Sep; 18(9):881-895. PubMed ID: 31475596
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycoengineered Outer Membrane Vesicles as a Platform for Vaccine Development.
    Valguarnera E; Feldman MF
    Methods Enzymol; 2017; 597():285-310. PubMed ID: 28935107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-Antigen Extraction, Purification, and Chemical Conjugation to a Carrier Protein.
    Micoli F; Giannelli C; Di Benedetto R
    Methods Mol Biol; 2021; 2183():267-304. PubMed ID: 32959249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic carbohydrate-based vaccines: challenges and opportunities.
    Mettu R; Chen CY; Wu CY
    J Biomed Sci; 2020 Jan; 27(1):9. PubMed ID: 31900143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential targets for next generation antimicrobial glycoconjugate vaccines.
    Micoli F; Costantino P; Adamo R
    FEMS Microbiol Rev; 2018 May; 42(3):388-423. PubMed ID: 29547971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on Sugar-Protein Connectivity in Salmonella O-Antigen Glycoconjugate Vaccines.
    De Benedetto G; Salvini L; Gotta S; Cescutti P; Micoli F
    Bioconjug Chem; 2018 May; 29(5):1736-1747. PubMed ID: 29697244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the production of recombinant glycoconjugate vaccines.
    Kay E; Cuccui J; Wren BW
    NPJ Vaccines; 2019; 4():16. PubMed ID: 31069118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
    Phalipon A; Costachel C; Grandjean C; Thuizat A; Guerreiro C; Tanguy M; Nato F; Vulliez-Le Normand B; Bélot F; Wright K; Marcel-Peyre V; Sansonetti PJ; Mulard LA
    J Immunol; 2006 Feb; 176(3):1686-94. PubMed ID: 16424198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs.
    Berti F; Micoli F
    Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Click chemistry compared to thiol chemistry for the synthesis of site-selective glycoconjugate vaccines using CRM
    Stefanetti G; Allan M; Usera A; Micoli F
    Glycoconj J; 2020 Oct; 37(5):611-622. PubMed ID: 32535667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical and novel strategies to develop a
    Barel LA; Mulard LA
    Hum Vaccin Immunother; 2019; 15(6):1338-1356. PubMed ID: 31158047
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycoconjugate vaccines against antimicrobial resistant pathogens.
    Sorieul C; Dolce M; Romano MR; Codée J; Adamo R
    Expert Rev Vaccines; 2023; 22(1):1055-1078. PubMed ID: 37902243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines.
    Stefanetti G; Rondini S; Lanzilao L; Saul A; MacLennan CA; Micoli F
    Vaccine; 2014 Oct; 32(46):6122-9. PubMed ID: 25192974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.